Unlike classic drug toxicity, CAR T-cells themselves do not target eye structures (the antigens like CD19 or BCMA are not expressed in ocular tissues), so direct “on-target/off tumor” attack on the eye is not expected. Here, CD19 is linked to neoplasm.